Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 4/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | ANPEP | P15144 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12201638 | 1.00 | USP2 (0.46) | USP2SMN1; SMN2HPGDTP53ALOX12 | |
| SCHEMBL105301 | 1.00 | USP2 (0.46) | USP2SMN1; SMN2HPGDTP53ALOX12 | |
| SCHEMBL9684500 | 0.94 | KMT2A (0.42) | USP2SMN1; SMN2HPGDTP53ALOX12 | |
| SCHEMBL8795712 | 0.86 | USP2 (0.46) | USP2SMN1; SMN2HPGDTP53ALOX12 | |
| SCHEMBL28463566 | 0.86 | ANPEP (0.47) | USP2SMN1; SMN2HPGDTP53ALOX12 | |
| SCHEMBL14018975 | 0.86 | USP2 (0.42) | USP2SMN1; SMN2HPGDTP53ALOX12 | |
| SCHEMBL6846193 | 0.86 | USP2 (0.42) | USP2SMN1; SMN2HPGDTP53ALOX12 | |
| SCHEMBL23781483 | 0.83 | ANPEP (0.42) | USP2SMN1; SMN2HPGDTP53ALOX12 | |
| SCHEMBL20093612 | 0.83 | USP2 (0.40) | USP2SMN1; SMN2HPGDTP53ALOX12 | |
| SCHEMBL15671001 | 0.83 | ANPEP (0.45) | USP2SMN1; SMN2HPGDTP53ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230013585-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | GILEAD SCIENCES, INC. | 2023-01-19 | — | — | US | disclosed |
| US-20210292330-A1 | PYRROLIDINE-FUSED HETEROCYCLES | ERASCA, INC. | 2021-09-23 | — | — | US | disclosed |
| US-11071730-B2 | Substituted 6-azabenzimidazole compounds | GILEAD SCIENCES, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| US-20200171020-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | GILEAD SCIENCES, INC. | 2020-06-04 | — | — | US | disclosed |
| US-9951065-B2 | Benzimidazole and imadazopyridine carboximidamide compounds | GILEAD SCIENCES, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20160333009-A1 | BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS | GILEAD SCIENCES, INC. | 2016-11-17 | — | — | US | disclosed |
| US-8268998-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-09-18 | — | — | US | disclosed |
| US-20110245252-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-10-06 | — | — | US | disclosed |
| US-7982033-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-07-19 | — | — | US | disclosed |
| US-20100081662-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-01 | — | — | US | disclosed |
| US-20100016320-A1 | ARYL-SUBSTITUTED PYRAZOLE-AMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-01-21 | — | — | US | disclosed |
| US-7605273-B2 | Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-20 | — | — | US | disclosed |
| US-20080275092-A1 | ARYL-SUBSTITUTED PYRAZOLE-AMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275092-A1 | ARYL-SUBSTITUTED PYRAZOLE-AMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | MAPK6, CDK6, GRK6 | USP2 3980/4885SMN1; SMN2 3120/4885HPGD 1476/4885 |
| US-20100016320-A1 | ARYL-SUBSTITUTED PYRAZOLE-AMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | MAPK6, CDK6, GRK6 | USP2 3980/4885SMN1; SMN2 3120/4885HPGD 1476/4885 |
| US-20100081662-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | NTRK2, NTRK3, NTRK1 | USP2 4713/4885SMN1; SMN2 3634/4885HPGD 2268/4885 |
| US-20210292330-A1 | PYRROLIDINE-FUSED HETEROCYCLES | SDHB, CCNI, SDHA | USP2 3915/4885SMN1; SMN2 2108/4885HPGD 109/4885 |
| US-20110245252-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | NTRK2, NTRK3, NTRK1 | USP2 4713/4885SMN1; SMN2 3634/4885HPGD 2268/4885 |
| US-20160333009-A1 | BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS | IDO1, IDO2, INMT | USP2 1814/4885SMN1; SMN2 1776/4885HPGD 784/4885 |
| US-11071730-B2 | Substituted 6-azabenzimidazole compounds | CDK6, HIPK1, DCK | USP2 2073/4885SMN1; SMN2 4077/4885HPGD 539/4885 |
| US-20200171020-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | CDK6, HIPK1, DCK | USP2 2073/4885SMN1; SMN2 4077/4885HPGD 539/4885 |
| US-20230013585-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | CDK6, HIPK1, DCK | USP2 2073/4885SMN1; SMN2 4077/4885HPGD 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.